Lantern Pharma (LTRN) Current Leases (2021 - 2026)

Lantern Pharma (LTRN) has reported Current Leases for 6 consecutive years, with $39715.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases fell 69.8% year-over-year to $39715.0; the trailing twelve-month figure through Jun 2026 stood at $39715.0 (down 69.8% YoY), and the FY2025 full-year result was $78539.0, down 58.84% from the prior year.
• Current Leases eased to $39715.0 in Q2 2026 per LTRN's latest filing, from $59076.0 in the prior quarter.
• Across five years, Current Leases topped out at $197291.0 in Q3 2024 and bottomed at $39715.0 in Q2 2026.
• Historically, Current Leases has averaged $124807.4 across 5 years, with a median of $131110.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Current Leases surged 227.05% in 2023, then plunged 69.8% in 2026.
• Over 5 years, Current Leases stood at $52890.0 in 2022, then soared by 227.05% to $172975.0 in 2023, then increased by 10.31% to $190814.0 in 2024, then slumped by 58.84% to $78539.0 in 2025, then plunged by 49.43% to $39715.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $39715.0, $59076.0, and $78539.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.